Pieris Pharmaceuticals, Inc.

  • Home
  • About
  • Platform
  • Pipeline
  • Patients
  • Investors
    • Overview
    • News & Events
    • Publications
    • Presentations
    • Financial Results
    • Stock Data
    • SEC Filings
    • Governance
  • Careers
    • Job Openings
  • Contact
Jan 19, 2021 8:00am EST

FDA Lifts Partial Clinical Hold on PRS-343 Phase 1 Studies

Nov 10, 2020 8:00am EST

Pieris Pharmaceuticals to Participate in Upcoming Investor Conferences

Nov 04, 2020 7:00am EST

Pieris Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update

Oct 28, 2020 8:00am EDT

Pieris Pharmaceuticals to Host Third Quarter 2020 Investor Call and Corporate Update on November 4, 2020

Sep 20, 2020 11:00am EDT

Pieris Pharmaceuticals Presents Updated Data from Phase 1 Monotherapy and Atezolizumab Combination Studies of 4-1BB/HER2 Bispecific PRS-343 at the European Society for Medical Oncology (ESMO) Virtual Congress 2020

Sep 03, 2020 4:30pm EDT

Pieris Pharmaceuticals to Participate in Upcoming Investor Conferences

Aug 10, 2020 7:00am EDT

Pieris Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate Update

Aug 10, 2020 6:30am EDT

Pieris and Lilly Enter Into a Clinical Trial Collaboration to Evaluate Combination of PRS-343 With Ramucirumab and Paclitaxel in Gastric Cancer

Aug 03, 2020 8:00am EDT

Pieris Pharmaceuticals to Host Second Quarter 2020 Investor Call and Corporate Update on August 10, 2020

Jul 23, 2020 8:00am EDT

Pieris Pharmaceuticals Announces Oral Presentation of Phase 1 Data for 4-1BB/HER2 Bispecific PRS-343 at European Society for Medical Oncology (ESMO) Virtual Congress 2020

  • Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • …25
  • Next
RSS
© 2023 Pieris Pharmaceuticals, Inc. All Rights Reserved.
Imprint Privacy Policy Disclaimer Sitemap Contact Us Manage Cookie Preferences